ELND 005

Drug Profile

ELND 005

Alternative Names: AZD-103; ELND-005; Quercinitol; Scyllitol; Scyllo-inositol; Scyllocyclohexanehexol

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Transition Therapeutics
  • Developer Speranza Therapeutics; Transition Therapeutics
  • Class Antidementias; Cyclohexanols; Nootropics; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Phase II Cognition disorders; Down syndrome
  • Discontinued Bipolar disorders

Most Recent Events

  • 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
  • 15 Oct 2015 Efficacy and safety data from the phase II/III HARMONY AD trial released by Transition Therapeutics
  • 07 Jul 2015 Elan Pharmaceuticals terminates a phase II extension trial for Alzheimer's disease (for treatment of agitation and aggression) (In adults, In the elderly) in USA, Canada, Spain and United Kingdom (NCT01766336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top